Pulmozyme for bronciectasis -pro
Daily administration of Pulmozyme (dornase alfa) (dornase alpha) Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In patients with an FVC 40% of predicted, daily administration of Pulmozyme (dornase alfa) has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
IN bronciectasis, unfortunately, dornase appears to be ineffective and even potentially harmful.
Pulmo- zyme) breaks down the DNA released at the site of infection by the neutrophils. DNA causes the sputum to become thick and tenacious; rhDNase makes the sputum less viscid and therefore
easier to expectorate. This has been shown in a number of studies to be beneficial in CF.
The potential for rhDNase to favourably influence symptoms in bronchiectasis has not been
tested in children, but it has been well studied in adults and there is no evidence of benefit. Indeed, there is evidence of worsening lung function with rhDNase use in bronchiectasis1.
Daily administration of Pulmozyme (dornase alfa) (dornase alpha) Inhalation Solution in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function. In patients with an FVC 40% of predicted, daily administration of Pulmozyme (dornase alfa) has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
IN bronciectasis, unfortunately, dornase appears to be ineffective and even potentially harmful.
Pulmo- zyme) breaks down the DNA released at the site of infection by the neutrophils. DNA causes the sputum to become thick and tenacious; rhDNase makes the sputum less viscid and therefore
easier to expectorate. This has been shown in a number of studies to be beneficial in CF.
The potential for rhDNase to favourably influence symptoms in bronchiectasis has not been
tested in children, but it has been well studied in adults and there is no evidence of benefit. Indeed, there is evidence of worsening lung function with rhDNase use in bronchiectasis1.